Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients

Retina

Volumn 31, Issue 5, 2011, Pages 915-923

  Boyer, David S ^a   Faber, David ^b   Gupta, Sunil ^c   Patel, Sunil S ^d   Tabandeh, Homayoun ^a   Li, Xiao Yan ^e   Liu, Charlie C ^e   Lou, Jean ^e   Whitcup, Scott M ^e  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b Rocky Mountain Retina Consultants   (United States)

^c Retina Specialists Pensacola   (United States)

^d Retina Research   (United States)

^e ALLERGAN INC   (United States)

Author keywords

Clinical trial; corticosteroid; dexamethasone; diabetic retinopathy; macular edema; optical coherence tomography; therapy; visual acuity; vitrectomy

Indexed keywords

DEXAMETHASONE;

ADULT; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FEMALE; HUMAN; IMPLANT; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RETINA; SIDE EFFECT; THICKNESS; TREATMENT DURATION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 79955558683     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318206d18c     Document Type: Article

References (24)

1. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
2. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417. (Pubitemid 12143608)
3. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25:556-560.
4. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686. (Pubitemid 36520063)
5. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
6. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009;116:1151-1157.
7. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
8. Nguyen QD, Shah SM, Heier JS, et al; READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.
9. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126. (Pubitemid 46963178)
10. Haller JA, Dugel P,Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46-51.
11. Kuppermann BD, Blumenkranz MS, Haller JA, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317. (Pubitemid 46425557)
12. Welty D, Kuppermann BD, Chang-lin JE, et al. Dexamethasone posterior segment drug delivery system: pharmacokinetics in vitrectomized and non-vitrectomized eyes. Paper presented at 25th Annual Meeting of the American Society of Retina Specialists; December 1-5, 2007; Indian Wells, CA. Abstract 3597.
13. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
14. Sakamoto A, Nishijima K, Kita M, et al. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2009;247:1325-1330.
15. Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010;30:774-780.
16. Gandorfer A, Messmer EM, UlbigMW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 2000;20:126-133. (Pubitemid 30395706)
17. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations. Eye (Lond) 2006;20:674-680. (Pubitemid 43880585)
18. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomywith internal limitingmembrane removal in diabetic macular edema. Retina 2007;27:557-566. (Pubitemid 46905145)
19. Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010;117:1087-1093.
20. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
21. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1459.
22. Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol 2009; 20:99-103.
23. Morello CM. Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm 2007;64:S3-S7. (Pubitemid 350202222)
24. Goff MJ, McDonald HR, Johnson RN, et al. Causes and treatment of vitreous hemorrhage. Compr Ophthalmol Update 2006;7:97-111. (Pubitemid 44174747)